focus -WSS

focus

author：hotspot 2025-09-29 01:37:34 - browse：111

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： 5 dead in mass shooting on Caribbean island of St. Vincent: Police

WSS

US jobless claims fall again as labor market continues to flash strength

Gene therapy for Afghan refugees’ infant will be fully covered

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

A protest over insulin prices is seen as a fight for life

Extensive review finds private equity owners jack up cost of care

Why Novartis is going to walk from its acquisition of MorphoSys

Wikipedia

focus

entertainment

How to save PrEP access — and even expand it

Cano Health’s bankruptcy is a warning for Medicare Advantage

Wildfire smoke exposes gaps in outdoor worker protections

Sanders wants to replace patents with prizes for drug inventions

23andMe had bad news about my health. I wish a person had delivered it

Sanders wants to replace patents with prizes for drug inventions

Affirmative action in medical school literally saved lives

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Wildfire smoke exposes gaps in outdoor worker protections

340B reform proposal comes out of Senate working group

Wikipedia

Johnson & Johnson sued for allegedly overpaying for workers' drugs

US jobless claims fall again as labor market continues to flash strength

The Biogen Aduhelm mess could happen again

Judge denies Trump's request for new trial in E. Jean Carroll case

Scientists grapple with ethics of stem cell research

340B reform proposal comes out of Senate working group

Wikipedia

Wikipedia

focus

focus